GLSI
NASDAQ
US
Greenwich LifeSciences, Inc. - Common stock
$22.82
▼ $-0.14
(-0.61%)
Vol 54K
2
Quality Score
fail
Rev ✗
NI ✗
>IPO ✗
Mkt Cap
$291.1M
ROE
-1042.8%
D/E
0.00
Beta
1.59
52W
$8–$22
Wall Street Consensus
8 analysts · Apr 20262
Strong Buy
5
Buy
1
Hold
0
Sell
0
Strong Sell
87.5%
Buy Rating
Price Chart
Similar Stocks
IRD
Opus Genetics Inc
$138.6M
XFOR
X4 Pharmaceuticals Inc
$349.7M
NGNE
Neurogene Inc
$319.1M
FBRX
Forte Biosciences Inc
$341.6M
SRZN
Surrozen Inc
$193.7M
PALI
Palisade Bio Inc
$350.2M
CLYM
Climb Bio Inc
$272.7M
RZLT
Rezolute Inc
$218.8M
OVID
Ovid Therapeutics Inc
$116.1M
FHTX
Foghorn Therapeutics Inc
$305.4M
Earnings
Beat rate: 25.0%| Quarter | EPS Est | EPS Act | Surprise |
|---|---|---|---|
| Sep 2025 | $-0.30 | $-0.30 | +$0.00 |
| Jun 2025 | $-0.24 | $-0.30 | $-0.06 |
| Mar 2025 | $-0.24 | $-0.25 | $-0.01 |
| Dec 2024 | $-0.21 | $-0.61 | $-0.40 |
Quarterly Revenue & Earnings
| Quarter | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -$2.7M | -$8.0M | -$3.3M | -$4.0M | -$4.2M |
Fundamentals Trend
| Metric | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -700.9% | -700.9% | -700.9% | -700.9% | -700.9% | -1042.8% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 1.85 | 1.85 | 1.85 | 1.85 | 1.85 | 2.35 |
Key Ratios
ROA (TTM)
-565.5%
P/B
58.3
EPS (TTM)
$-1.46
CF/Share
$-0.48
52W High
$22.31
52W Low
$7.78
$7.78
52-Week Range
$22.31
Financial Health
Free Cash Flow
-$2.7M
Cash
$3.8M
As of Sep 30, 2025
How does GLSI compare to Biotechnology peers?
Peer group: Micro-cap Biotechnology (All) · 528 companies
GLSI valuation vs Biotechnology peers
P/E ratio
—
▼
0%
below
peers
(18.8)
vs Peers
vs Industry
Undervalued
P/S ratio
—
▼
0%
below
peers
(12.9)
vs Peers
vs Industry
Overvalued
P/B ratio
58.3
▲
2268%
above
peers
(2.5)
vs Peers
vs Industry
Overvalued
Div yield
—
▼
0%
below
peers
(0.0%)
vs Peers
vs Industry
Low yield
GLSI profitability vs Biotechnology peers
ROE
-1042.8%
▼
1449%
below
peers
(-67.3%)
vs Peers
vs Industry
Weak
Net margin
—
▼
0%
below
peers
(-286.8%)
vs Peers
vs Industry
Top tier
Gross margin
—
▼
0%
below
peers
(78.6%)
vs Peers
vs Industry
In line
ROA
-565.5%
▼
1111%
below
peers
(-46.7%)
vs Peers
vs Industry
Weak
GLSI financial health vs Biotechnology peers
D/E ratio
0.0
▼
0%
below
peers
(0.0)
vs Peers
vs Industry
Low debt
Current ratio
2.4
▼
47%
below
peers
(4.4)
vs Peers
vs Industry
Low liquidity
Beta
1.6
▲
64%
above
peers
(1.0)
vs Peers
vs Industry
More volatile
GLSI fundamentals radar
GLSI
Peer median
Industry
GLSI profitability vs leverage
Bubble size = market cap · X = net margin · Y = D/E ratio
GLSI vs peers: key metrics
Insider Activity
NeutralBuys
0
Sells
0
PATEL SNEHAL
Chief Executive Officer · Jan 13
1800 shs
PATEL SNEHAL
Chief Executive Officer · Jan 12
2900 shs
Last 90 days
Top Holders
Top 5: 7.25%Blackrock Inc.
2.68%
$8.3M
Vanguard Group Inc
2.14%
$6.6M
Geode Capital Management, L…
1.09%
$3.4M
State Street Corporation
0.71%
$2.2M
Credit Agricole S.A.
0.63%
$1.9M
As of Dec 31, 2025